Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Современная антигипертензивная терапия: место β-адреноблокатора бисопролола
Современная антигипертензивная терапия: место β-адреноблокатора бисопролола
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Кобалава Ж.Д., Гудкова К.М. Секреты артериальной гипертонии: ответы на ваши вопросы. М., 2004; с. 172.
2. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620–5.
3. Pahor M, Guralnik JM, Corti MC et al. Long-term survival and uses of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 49: 1191–7.
4. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2133.
5. Brown MJ. The causes of essencial hypertension. Br J Clin Pharm 1996; 42: 21–7.
6. O'Shaughnessy KM, Dickerson C, Thurston D et al. The gain-of-fuction G389R variant of the beta-1-adrenoreceptor does not influence blood pressure or heart rate responce to beta-blockade in hypertensive subjects. Clin Sci (Lond) 2000; 99 (3); 231–2.
7. Van den Meiracker AH, Man AJ, van Eck HJ et al. Hemodynamic and hormanal adaptations to beta-adrenoreceptor blockade. A 24-hour study of acebutolol, atenolo. pindolol, and propranolol in hypertensive patients. Circulation 1988; 78; 957–68.
8. Carlsberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–9.
9. Lindholm LH, Carlsberg B, Samuelsson Should b-blockers first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53.
10. Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония: ключи к диагностике и лечению. М., 2007; с. 198.
11. Jacob S et al. Am О Hypertens 1998; 11: 1258–65.
12. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
13. Mancia G, Grassi G, Zanchetti A. New-onset diabetes andantihypertensive drugs. J Hypertens 2006; 24: 3–10.
14. Zanchetti A, Hennig M, Baurecht H et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens 2007; 25: 2463–70.
15. Barr EL, Zimmet PZ, Welborn TA et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes. Obesity and Lifestyle Study (AusDiab). Circulation 2007; 116: 151–7.
16. Mozaffarian D, Marfisi R, Levantesi G et al. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet 2007; 370: 667–75.
17. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130–4.
18. Gress TW, Nieto J, Shahar У et al. N Eng J Med 2000; 342: 905–12.
19. Dahlӧf B et al. ASCOT Investigators. Lancet 2005; 366: 895.
20. Lindholm LH et al. Lancet 2002; 359: 1004–10.
21. Lindholm LH, Persson M, Alaupovic F et al. Hypertens 2003; 21 (8): 1563–74.
22. Bakris GL et al. JAMA 2004; 292: 2227–36.
23. Benetos et al. J Hypertens 2002.
2. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620–5.
3. Pahor M, Guralnik JM, Corti MC et al. Long-term survival and uses of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 49: 1191–7.
4. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2133.
5. Brown MJ. The causes of essencial hypertension. Br J Clin Pharm 1996; 42: 21–7.
6. O'Shaughnessy KM, Dickerson C, Thurston D et al. The gain-of-fuction G389R variant of the beta-1-adrenoreceptor does not influence blood pressure or heart rate responce to beta-blockade in hypertensive subjects. Clin Sci (Lond) 2000; 99 (3); 231–2.
7. Van den Meiracker AH, Man AJ, van Eck HJ et al. Hemodynamic and hormanal adaptations to beta-adrenoreceptor blockade. A 24-hour study of acebutolol, atenolo. pindolol, and propranolol in hypertensive patients. Circulation 1988; 78; 957–68.
8. Carlsberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–9.
9. Lindholm LH, Carlsberg B, Samuelsson Should b-blockers first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53.
10. Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония: ключи к диагностике и лечению. М., 2007; с. 198.
11. Jacob S et al. Am О Hypertens 1998; 11: 1258–65.
12. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
13. Mancia G, Grassi G, Zanchetti A. New-onset diabetes andantihypertensive drugs. J Hypertens 2006; 24: 3–10.
14. Zanchetti A, Hennig M, Baurecht H et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens 2007; 25: 2463–70.
15. Barr EL, Zimmet PZ, Welborn TA et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes. Obesity and Lifestyle Study (AusDiab). Circulation 2007; 116: 151–7.
16. Mozaffarian D, Marfisi R, Levantesi G et al. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet 2007; 370: 667–75.
17. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130–4.
18. Gress TW, Nieto J, Shahar У et al. N Eng J Med 2000; 342: 905–12.
19. Dahlӧf B et al. ASCOT Investigators. Lancet 2005; 366: 895.
20. Lindholm LH et al. Lancet 2002; 359: 1004–10.
21. Lindholm LH, Persson M, Alaupovic F et al. Hypertens 2003; 21 (8): 1563–74.
22. Bakris GL et al. JAMA 2004; 292: 2227–36.
23. Benetos et al. J Hypertens 2002.
Авторы
О.А.Манешина, С.Б.Ерофеева, Ю.Б.Белоусов, А.В.Соколов, И.Ф.Тищенкова
ГОУ ВПО РГМУ Минздравсоцразвития РФ; ГКБ №61, Москва
ГОУ ВПО РГМУ Минздравсоцразвития РФ; ГКБ №61, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.